VANCOUVER, Oct. 16 /CNW/ - CRH Medical Corporation (CRM:TSX-V) announced
today that it filed with the United States Patent and Trademark Office a new
U.S. patent application entitled, "Elastic Band Ligation Device and Method for
Treatment of Hemorrhoids". The Company intends to file corresponding patent
applications in important markets throughout the world.
The Company currently has patent protection in several countries covering
its core technology and related treatment methods. The new patent application
includes a number of improvements that increase the efficiency of the
Company's technology and is expected to extend the Company's patent protection
Commenting on the new patent application, Edward Wright, Chief Executive
Officer stated, "To date, we have successfully treated over 50,000 patients in
the United States with our proprietary technology. This new patent application
represents our commitment to providing patients with the most advanced
hemorrhoid treatment technology and methods available. As we broaden our scope
of intellectual property, we can also explore the possibility of expanding
into certain international markets. Although in the near term we will continue
to concentrate solely on the U.S. market employing our current business model,
our strong proprietary position affords us the opportunity to consider
alternative distribution strategies in other countries."
About CRH Medical Corporation:
CRH Medical Corporation is utilizing the first single use, patented,
disposable, hemorrhoid banding system through its Center for Colorectal Health
facilities. According to the National Institute of Health approximately 50% of
the U.S. population will develop hemorrhoids by age 50. CRH Medical is opening
its Center for Colorectal Health facilities in the United States specializing
in the treatment of hemorrhoids, anal fissures, and colon cancer screening and
plans to significantly increase the number of Centers for Colorectal Health
across the U.S. to address this underserved market. The Company's goal is to
become the preeminent resource on colorectal health for consumers and medical
professionals in North America.
The information in this news release contains so-called "forward-looking"
statements. These include statements regarding CRH Medical expectations,
beliefs, intentions or strategies for the future, which may be indicated by
words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we
believe", "CRH Medical believes", "management believes" and similar language.
All forward-looking statements are based on CRH Medical current expectations
and are subject to risks and uncertainties and to assumptions made.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: Dean Linden, Corporate Communications, CRH
Medical Corporation at (604) 633-1440 or email@example.com; Additional
information may also be found by visiting the Company's website at
www.crhmedcorp.com or the SEDAR website at www.sedar.com